A study of 231 cancer patients found that the use of duloxetine (Cymbalta) reduced chemotherapy induce peripheral neuropathy. Patients either recieved Cymbalta or a placebo; in the Cymbalta arm, 59% … Continued
According to research published in March 6 in the journal Nature, researchers have discovered a possible origin of epithelial ovarian cancer. The origin of ovarian cancer is unclear, making the development … Continued
On Tuesday, April 2, the U.S. Preventive Services Task Force (USPSTF) released its draft recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. The USPSTF recommends … Continued
Research published today in the Journal of the American Medical Association showed that the depression and anxiety drug duloxetine effectively treated painful chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy occurs in … Continued
At this year’s Society of Gynecologic Oncology (SGO) Annual Meeting, numerous presentations and posters explored issues related to ovarian cancer, some of which are summarized below. This year’s SGO Annual … Continued
A collaboration of more than 130 institutions analyzing data from more than 200,000 people found two new genetic markers increasing a woman’s risk of developing ovarian cancer. New risk-modifying loci … Continued
As part of a huge international effort involving more than 100 institutions and genetic tests on 200,000 people, researchers have discovered dozens of signposts in DNA that can help reveal … Continued
A study by researchers from the Fred HutchinsonCancer Research Center in Seattle found that women working the night shift may be at higher risk for ovarian cancer. The study of … Continued
In research published online on March 11, 2013 in the Journal of Clinical Oncology, researchers report on the results of a phase III, double-blind, placebo-controlled multicenter study that evaluated whether using … Continued
From March 9-12, 2013 top women’s cancer doctors from all over the world met in Los Angeles for the Society of Gynecologic Oncology‘s Annual Meeting on Women’s Cancer. Lots of exciting … Continued
Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read … Continued
The New York Times reported today on a study that found most women with ovarian cancer receive inadequate care. The article discusses research presented at the 2013 meeting of the … Continued
Get email updates about research news, action alerts, and ways to join the fight.
